Novavax and XOMA Showing Investors Strong Gains in 2012 as Biotech Industry Continues to Thrive Five Star Equities Provides Stock Research on Novavax and XOMA
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 07/09/12 -- Despite the recent economic slowdown, the Biotech Industry has been home to some of the strongest performers in the market in 2012. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 39 percent and 36 percent, respectively. As the world continues to face evolving health challenges the discoveries of new therapeutics and vaccines are critical. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Novavax, Inc. (NASDAQ: NVAX) and XOMA Corporation (NASDAQ: XOMA).
Access to the full company reports can be found at:
Expiring patents have been a major dilemma for pharmaceutical companies. New products that are being introduced are not expected to generate the same level of revenues of the products that have lost patent protection. The Obama administration is currently analyzing a proposal in which the exclusivity period for biologics would be cut down by 5 years. Mergers & Acquisitions activity is expected to pick up in 2012 as companies scramble to look to make up for lost revenues. M&A allow companies to acquire products that are already proven in the market place without the hassle and costs associated with research and development.
"Many of the pharmaceutical companies started producing everything in-house out of their own R&D organizations and over time they've failed to produce enough that way. So the industry is now coalescing around a 50-50 model of half on your own and half bought in. There are some things we'll do for ourselves but we need to be constantly on the lookout for new technologies," said Angus Russell, Chief Executive of Shire PLC.
Five Star Equities releases regular market updates on companies in the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous stock reports and industry newsletters.
Novavax is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide. Gregory Glenn, M.D., SVP and Chief Medical Officer of Novavax recently reported that the findings from the recent Phase I trial were consistent with the preclinical results in relevant animal models. Shares of the company have soared over 50 percent year-to-date.
XOMA combines a portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research, with its recently launched commercial operations. XOMA focuses its antibody research and development on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases.
Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
Contact:
Five Star Equities
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 09.07.2012 - 12:20 Uhr
Sprache: Deutsch
News-ID 163177
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Commercial & Investment Banking
Diese Pressemitteilung wurde bisher 181 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novavax and XOMA Showing Investors Strong Gains in 2012 as Biotech Industry Continues to Thrive Five Star Equities Provides Stock Research on Novavax and XOMA"
steht unter der journalistisch-redaktionellen Verantwortung von
Five Star Equities (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
